CHP
KDNY

Cable Hill Partners’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Cable Hill Partners’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-150
Closed -$8K – 1040
2017
Q3 		$8K Buy
+150
New +$8.91K ﹤0.01% 654

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cable Hill Partners's KDNY Position: Q4 2017 in Review

Cable Hill Partners sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2017, closing a stake of 150 shares — an estimated $8K sold.

Cable Hill Partners first reported a position in KDNY in Q3 2017 and held it in 1 quarter. The position peaked at $8K in Q3 2017. 94 funds tracked by Wall St. Rank hold KDNY as of Q4 2017.

  • Cable Hill Partners reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Cable Hill Partners sold 150 Chinook Therapeutics, Inc. Common Stock shares in Q4 2017, an estimated $8K.
  • Cable Hill Partners first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Cable Hill Partners's Chinook Therapeutics, Inc. Common Stock position peaked at $8K in Q3 2017.
  • 94 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2017.

Based on Cable Hill Partners's 13F filing for Q4 2017, filed 22 Feb 2018.